Overview

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus, and European Union (EU)-Lantus

Status:
COMPLETED
Trial end date:
2025-07-03
Target enrollment:
Participant gender:
Summary
Single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS Glargine (G), United States (US)-Lantus, and European Union (EU)-Lantus
Phase:
PHASE1
Details
Lead Sponsor:
Xentria, Inc.